[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Janux Therapeutics Inc (JANX)

Janux Therapeutics Inc (JANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 985,529
  • Shares Outstanding, K 61,137
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -113,630 K
  • EBIT $ -144 M
  • EBITDA $ -159 M
  • 60-Month Beta 2.50
  • Price/Sales 97.82
  • Price/Cash Flow N/A
  • Price/Book 1.05

Options Overview Details

View History
  • Implied Volatility 58.80% (+6.17%)
  • Historical Volatility 38.07%
  • IV Percentile 15%
  • IV Rank 13.04%
  • IV High 181.74% on 11/25/25
  • IV Low 40.38% on 06/30/26
  • Expected Move (DTE 4) 0.89 (5.54%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 57
  • Volume Avg (30-Day) 523
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 9,794
  • Open Int (30-Day) 8,519
  • Expected Range 15.23 to 17.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 8
  • High Estimate $-0.04
  • Low Estimate $-0.67
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) -23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.57 +10.64%
on 07/28/26
16.83 -4.25%
on 08/11/26
+0.34 (+2.15%)
since 07/14/26
3-Month
12.98 +24.14%
on 06/10/26
16.91 -4.64%
on 07/09/26
+1.73 (+12.02%)
since 05/14/26
52-Week
12.12 +33.00%
on 02/05/26
35.34 -54.39%
on 11/26/25
-8.85 (-35.44%)
since 08/14/25

Most Recent Stories

More News
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts JANX014 Phase 1 study continues enrolling...

JANX : 16.12 (+0.75%)
Janux Therapeutics: Whether the Pipeline Justifies the Valuation Gets Its First Real Test

Barchart Research What to Expect from JANX Earnings JANX Generated August 5, 2026 Current Price $16.00 EPS Estimate $$-0.26 Consensus Rating Moderate Buy Average Move 2.88% Janux Therapeutics: Whether...

JANX : 16.12 (+0.75%)
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation...

JANX : 16.12 (+0.75%)
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further...

JANX : 16.12 (+0.75%)
Stocks Retreat on Middle East Peace Doubts

The S&P 500 Index ($SPX ) (SPY ) today is down -0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.24%. June E-mini S&P futures...

ALK : 45.96 (-3.24%)
MSTR : 93.04 (-4.18%)
UAL : 125.34 (-0.80%)
AVGO : 392.99 (-5.94%)
INTU : 345.66 (-3.53%)
GLXY : 21.66 (+3.39%)
$IUXX : 30,046.14 (-0.13%)
COIN : 148.47 (-3.53%)
ZNU26 : 108-220 (+0.10%)
ESU26 : 7,814.75 (+0.12%)
NCLH : 19.01 (-2.76%)
STX : 973.44 (+5.65%)
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

- JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority...

JANX : 16.12 (+0.75%)
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate...

JANX : 16.12 (+0.75%)
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population...

JANX : 16.12 (+0.75%)
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed...

JANX : 16.12 (+0.75%)
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated...

JANX : 16.12 (+0.75%)

Business Summary

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

See More

Key Turning Points

3rd Resistance Point 16.83
2nd Resistance Point 16.53
1st Resistance Point 16.32
Last Price 16.12
1st Support Level 15.81
2nd Support Level 15.51
3rd Support Level 15.30

See More

52-Week High 35.34
Fibonacci 61.8% 26.47
Fibonacci 50% 23.73
Fibonacci 38.2% 20.99
Last Price 16.12
52-Week Low 12.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.